“Our goal is to treat patients on a more individualized basis, matching the right drugs with the right patients,” said Anil Potti, M.D., an oncologist and researcher in the DCCC and the IGSP. “The combination of these two methods, one of which uses the clinical description of patient’s breast cancer and the other which looks at gene expression at a molecular level in a patient’s tumor, may allow us to do that with unprecedented accuracy. This represents a robust approach to personalizing treatment strategies in patients suffering from breast cancer.”
The findings appear in the April 2, 2008 issue of the Journal of the American Medical Association. The study was funded by the Jimmy V Foundation, the American Cancer Society and the Emilene Brown Research Fund.
Researchers looked at almost 1000 breast tumor samples, and corresponding patient data, and applied existing technology -- a computerized system called Adjuvant! -- to assess clinical characteristics and make predictions of recurrence based on them. By then comparing gene expression in these tumor samples, the researchers were able to see specific genomic patterns among patients with aggressive cancers, and those whose cancers were less likely to recur.
“We knew from previous studies that Adjuvant! tends to overestimate disease recurrence in younger patients,” Potti said. “We hypothesized that genomic profiling could be a complementary tool that would more precisely define clinical outcomes, and could also help to aid in selecting the right drug for a given patient.”
By using the clinical and genomic tools together and cross-comparing data, the researchers were able to not only say that a particular patient has a “high” risk of recurrence, but they could be more specific; for instance, they could predict that a particular patient was 90 percent likely to see her cancer recur, Potti said.
“This is important because with this data, we might decide to treat this person more aggressively even than someone else who is considered ‘high risk’ but may have only a 60 percent likelihood of recurrence,” he said. “Moreover, we can identify specific options for chemotherapy in such patients as well, by correlating gene expression in a tumor with its response, or non-response, to certain chemotherapies.”
The findings have already been put into practice as part of several clinical trials at Duke for cancer patients. A tumor’s genomic make-up is being used to dictate the choice between a traditional chemotherapy regimen and an alternate drug that is more likely to benefit an individual patient. One such trial involving almost 300 patients with breast cancer is expected to start at Duke this spring.
Lauren Williams | EurekAlert!
New study shows nanoscale pendulum coupling
05.07.2019 | University of Barcelona
New unprinting method can help recycle paper and curb environmental costs
26.06.2019 | Rutgers University
Scientists have visualised the electronic structure in a microelectronic device for the first time, opening up opportunities for finely-tuned high performance electronic devices.
Physicists from the University of Warwick and the University of Washington have developed a technique to measure the energy and momentum of electrons in...
Scientists at the University Würzburg and University Hospital of Würzburg found that megakaryocytes act as “bouncers” and thus modulate bone marrow niche properties and cell migration dynamics. The study was published in July in the Journal “Haematologica”.
Hematopoiesis is the process of forming blood cells, which occurs predominantly in the bone marrow. The bone marrow produces all types of blood cells: red...
For some phenomena in quantum many-body physics several competing theories exist. But which of them describes a quantum phenomenon best? A team of researchers from the Technical University of Munich (TUM) and Harvard University in the United States has now successfully deployed artificial neural networks for image analysis of quantum systems.
Is that a dog or a cat? Such a classification is a prime example of machine learning: artificial neural networks can be trained to analyze images by looking...
An international research group led by scientists from the University of Bayreuth has produced a previously unknown material: Rhenium nitride pernitride. Thanks to combining properties that were previously considered incompatible, it looks set to become highly attractive for technological applications. Indeed, it is a super-hard metallic conductor that can withstand extremely high pressures like a diamond. A process now developed in Bayreuth opens up the possibility of producing rhenium nitride pernitride and other technologically interesting materials in sufficiently large quantity for their properties characterisation. The new findings are presented in "Nature Communications".
The possibility of finding a compound that was metallically conductive, super-hard, and ultra-incompressible was long considered unlikely in science. It was...
An interdisciplinary research team at the Technical University of Munich (TUM) has built platinum nanoparticles for catalysis in fuel cells: The new size-optimized catalysts are twice as good as the best process commercially available today.
Fuel cells may well replace batteries as the power source for electric cars. They consume hydrogen, a gas which could be produced for example using surplus...
24.06.2019 | Event News
29.04.2019 | Event News
17.04.2019 | Event News
18.07.2019 | Health and Medicine
18.07.2019 | Life Sciences
18.07.2019 | Health and Medicine